Frost & Sullivan: Strong Pipeline of Monoclonal Antibodies (mAbs) Biosimilars in the US and Europe Lends Impetus to Global Market

Description

Frost & Sullivan: Strong Pipeline ofFrost & Sullivan: Strong Pipeline of Monoclonal Antibodies (mAbs) Biosimilars in the US and Europe Lends Impetus to Global Market PR Newswire LONDON, Jan. 29, 2014 - The market is expected to soar from $1.

Informations

• Publié par: frost-sullivan
• Publié le: 29 janvier 2014
• Nombre de lectures: 6
• Langue: English

Extrait

Frost & Sullivan: Strong Pipeline of Monoclonal Antibodies (mAbs) Biosimilars in the US and Europe Lends Impetus to Global Market

PR Newswire

LONDON, Jan. 29, 2014

- The market is expected to soar from $1.2 billion of 2013 to $24 billion in 2019

The imminent entry of several companies, including big pharma, small biotech and generic participants, into the global biosimilars space will propel the market towards exponential growth. Already, Indian groups such as Dr. Reddy's Laboratories, Biocon and Reliance Life Sciences are making a concerted effort to enter the European market. Although these companies have not yet penetrated the European market due to the stringent regulatory pathway, new product launches are expected in the mid-term.